Cargando…

Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study

The aim of this multicentre study was to document the nephrotoxicity associated with ifosfamide and evaluate risk factors in 148 children and young people with sarcomas who underwent investigation of renal function on one occasion each, at a median of 6 (range 1–47) months after completion of ifosfa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Skinner, R, Cotterill, S J, Stevens, M C G
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2000
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374517/ https://www.ncbi.nlm.nih.gov/pubmed/10817497 http://dx.doi.org/10.1054/bjoc.2000.1214

Ejemplares similares

The influence of ifosfamide scheduling on acute nephrotoxicity in children.
por: English, M. W., et al.
Publicado: (1997)

The treatment of Wilms' tumour: results of the United Kingdom Children's Cancer Study Group (UKCCSG) second Wilms' tumour study
por: Mitchell, C, et al.
Publicado: (2000)

Ifosfamide nephrotoxicity in adult patients
por: Ensergueix, Gaël, et al.
Publicado: (2019)

Improved outcome in children with advanced stage B-cell non-Hodgkin's lymphoma (B-NHL): results of the United Kingdom Children Cancer Study Group (UKCCSG) 9002 protocol
por: Atra, A, et al.
Publicado: (2000)

Effect of Glutathione Depletion on Ifosfamide Nephrotoxicity in Rats
por: Garimella-Krovi, Sudha, et al.
Publicado: (2008)

Recruiting children into cancer trials–role of the United Kingdom Children's Cancer Study Group (UKCCSG)
por: Ablett, S, et al.
Publicado: (2003)

Dose-related nephrotoxicity of carboplatin in children
por: English, M W, et al.
Publicado: (1999)

Childhood cancer and ethnic group in Britain: a United Kingdom children's Cancer Study Group (UKCCSG) study.
por: Stiller, C. A., et al.
Publicado: (1991)

Treatment Outcomes of Childhood Medulloblastoma with the SIOP/UKCCSG PNET-3 Protocol
por: Kartal, İbrahim, et al.
Publicado: (2023)

Second malignancies in children treated for non-Hodgkin's lymphoma and T-cell leukaemia with the UKCCSG regimens.
por: Ingram, L., et al.
Publicado: (1987)

Conservative treatment followed by chemotherapy with doxorubicin and ifosfamide for cervical sarcoma botryoides in young females
por: Zanetta, G, et al.
Publicado: (1999)

Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study.
por: Stiller, C. A., et al.
Publicado: (1994)

Ifosfamide/etoposide alternating with high-dose methotrexate: evaluation of a chemotherapy regimen for poor-risk osteosarcoma
por: Michelagnoli, M P, et al.
Publicado: (1999)

Adjuvant low dose radiation in childhood non-Hodgkin's lymphoma (report from the United Kingdom Childrens' Cancer Study Group--UKCCSG).
por: Mott, M. G., et al.
Publicado: (1984)

Adjuvant low dose radiation in childhood T cell leukaemia/lymphoma (report from the United Kingdom Childrens' Cancer Study Group--UKCCSG).
por: Mott, M. G., et al.
Publicado: (1984)

Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature
por: Pelgrims, J, et al.
Publicado: (2000)

Incorporating ifosfamide into salvia oil-based nanoemulsion diminishes its nephrotoxicity in mice inoculated with tumor
por: AlMotwaa, Sahar M., et al.
Publicado: (2020)

Outcome in stage III non-Hodgkin's lymphoma in children (UKCCSG study NHL 86)--how much treatment is needed? United Kingdom Children's Cancer Study Group.
por: Pinkerton, C. R., et al.
Publicado: (1991)

Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity.
por: Bokemeyer, C., et al.
Publicado: (1996)

Cisplatin dose rate as a risk factor for nephrotoxicity in children.
por: Skinner, R., et al.
Publicado: (1998)

Childhood T-cell lymphoblastic lymphoma--does early resolution of mediastinal mass predict for final outcome? The United Kingdom Children's Cancer Study Group (UKCCSG).
por: Shepherd, S. F., et al.
Publicado: (1995)

Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours
por: Kosmas, C, et al.
Publicado: (2000)

Outcome and Toxicity of an Ifosfamide-Based Soft Tissue Sarcoma Treatment Protocol in Children. The Importance of Local Therapy
por: Yule, S. Murray, et al.
Publicado: (1998)

Pretreatment of ellagic acid protects ifosfamide-induced acute nephrotoxicity in rat kidneys: A mitochondrial, histopathological and oxidative stress approaches
por: Shabani, Mohammad, et al.
Publicado: (2023)

Ifosfamide, cisplatin and etoposide combination in locally advanced inoperable non-small-cell lung cancer: a phase II study
por: Scinto, A F, et al.
Publicado: (1999)

The growing pains of ifosfamide
por: Sprangers, Ben, et al.
Publicado: (2020)

Gemcitabine, Ifosfamide and Navelbine (GIN): activity and safety of a non-platinum-based triplet in advanced non-small-cell lung cancer (NSCLC)
por: Baldini, E, et al.
Publicado: (2001)

Risk Factors for Ifosfamide-Related Encephalopathy in Adult Cancer Patients: An Integrative Review
por: Lee Brink, Amanda, et al.
Publicado: (2020)

Single-Centre Experience of Systemic Treatment with Vincristine, Ifosfamide, and Doxorubicin Alternating with Etoposide, Ifosfamide, and Cisplatin in Adult Patients with Ewing Sarcoma
por: Requilé, Annelies, et al.
Publicado: (2017)

Examination of generational impacts of adolescent chemotherapy: Ifosfamide and potential for epigenetic transgenerational inheritance
por: Thompson, Ryan P., et al.
Publicado: (2022)

Hepatitis B Reactivation After Ifosfamide Therapy for Retroperitoneal Sarcoma
por: Chhibar, Purva, et al.
Publicado: (2016)

Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer
por: Sculier, J-P, et al.
Publicado: (2000)

AP-1 Transcription Factor JunD Confers Protection from Accelerated Nephrotoxic Nephritis and Control Podocyte-Specific Vegfa Expression
por: Cook, H. Terence, et al.
Publicado: (2011)

Pharmacokinetic Study of Perioperative Intravenous Ifosfamide
por: Van der Speeten, Kurt, et al.
Publicado: (2011)

The interaction of ifosfamide and aprepitant in gynecologic malignancies()
por: Shindorf, Mackenzie L., et al.
Publicado: (2013)

Ifosfamide-Induced Malignancy of Ureter and Bladder
por: Sannu, Aparna, et al.
Publicado: (2017)

Partial Fanconi Syndrome Induced by Ifosfamide
por: Das, Sulagna, et al.
Publicado: (2019)

Ifosfamide as a Cause of Fanconi Syndrome
por: Martinez, Daniel, et al.
Publicado: (2022)

Osteomalacia as a Late Metabolic Complication of Ifosfamide Chemotherapy in Young Adults: Illustrative Cases and Review of the Literature
por: Church, D. N., et al.
Publicado: (2007)

Serotonin Syndrome Complicating Treatment of Ifosfamide Neurotoxicity With Methylene Blue
por: Snyder, Matthew, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jt45s06dd5fottpol550u59pis